115 related articles for article (PubMed ID: 25397533)
1. The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study.
Rokx C; Blonk M; Verbon A; Burger D; Rijnders BJ
J Int AIDS Soc; 2014; 17(4 Suppl 3):19789. PubMed ID: 25397533
[TBL] [Abstract][Full Text] [Related]
2. Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis.
Stellbrink HJ; Antinori A; Pozniak A; Flamm J; Bredeek F; Patel K; Garner W; Piontkowsky D
J Int AIDS Soc; 2014; 17(4 Suppl 3):19793. PubMed ID: 25397537
[TBL] [Abstract][Full Text] [Related]
3. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
[TBL] [Abstract][Full Text] [Related]
4. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.
Rokx C; Verbon A; Rijnders BJ
AIDS Res Hum Retroviruses; 2015 Apr; 31(4):363-7. PubMed ID: 25625211
[TBL] [Abstract][Full Text] [Related]
5. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
[TBL] [Abstract][Full Text] [Related]
6. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
[TBL] [Abstract][Full Text] [Related]
7. Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.
Pérez-Hernández IA; Palacios R; Mayorga M; González-Doménech CM; Castaño M; Rivero A; Del Arco A; Lozano F; Santos J
J Int AIDS Soc; 2014; 17(4 Suppl 3):19795. PubMed ID: 25397539
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
[TBL] [Abstract][Full Text] [Related]
9. More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort.
Rokx C; Fibriani A; van de Vijver D; Verbon A; Schutten M; Gras L; Rijnders BJ
J Int AIDS Soc; 2014; 17(4 Suppl 3):19491. PubMed ID: 25394000
[TBL] [Abstract][Full Text] [Related]
10. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
Pinnetti C; Di Giambenedetto S; Maggiolo F; Lorenzini P; Fabbiani M; Tommasi C; Latini A; Ammassari A; Loiacono L; Sterrantino G; Bellagamba R; Boumis E; Antinori A; Zaccarelli M
J Int AIDS Soc; 2014; 17(4 Suppl 3):19812. PubMed ID: 25397556
[TBL] [Abstract][Full Text] [Related]
11. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
[TBL] [Abstract][Full Text] [Related]
12. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Soriano V; Arastéh K; Migrone H; Lutz T; Opravil M; Andrade-Villanueva J; Antunes F; Di Perri G; Podzamczer D; Taylor S; Domingo P; Gellermann H; de Rossi L;
Antivir Ther; 2011; 16(3):339-48. PubMed ID: 21555816
[TBL] [Abstract][Full Text] [Related]
13. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
Arasteh K; Ward D; Plettenberg A; Livrozet JM; Orkin C; Cordes C; Guo J; Wang E; Yong CL; Robinson P; Quinson A
HIV Med; 2012 Apr; 13(4):236-44. PubMed ID: 22136068
[TBL] [Abstract][Full Text] [Related]
14. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
Allavena C; Dailly E; Reliquet V; Bonnet B; Pineau S; André-Garnier E; Boutoille D; Bouquié R; Raveleau A; Bouchez S; Billaud E; Raffi F
J Antimicrob Chemother; 2014 Oct; 69(10):2804-8. PubMed ID: 24907142
[TBL] [Abstract][Full Text] [Related]
15. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
Taramasso L; Di Biagio A; Riccardi N; Briano F; Di Filippo E; Comi L; Mora S; Giacomini M; Gori A; Maggiolo F
PLoS One; 2019; 14(10):e0223181. PubMed ID: 31603906
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial.
Petchkum P; Sungkanuparph S; Kiertiburanakul S; Phuphuakrat A
Open Forum Infect Dis; 2019 Apr; 6(4):ofz155. PubMed ID: 31041351
[TBL] [Abstract][Full Text] [Related]
17. Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia.
Thamrongwonglert P; Chetchotisakd P; Anunnatsiri S; Mootsikapun P
HIV Clin Trials; 2016 Feb; 17(1):12-6. PubMed ID: 26739573
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.
Bernaud C; Khatchatourian L; Rodallec A; Hall N; Perre P; Morrier M; Pineau S; Jovelin T; André-Garnier E; Raffi F; Allavena C
Infect Dis (Lond); 2016 Oct; 48(10):754-9. PubMed ID: 27389932
[TBL] [Abstract][Full Text] [Related]
19. Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV.
Munderi P; Were E; Avihingsanon A; Mbida PAM; Mohapi L; Moussa SB; Jansen M; Bicer C; Mohammed P; van Delft Y
South Afr J HIV Med; 2019; 20(1):949. PubMed ID: 31392036
[TBL] [Abstract][Full Text] [Related]
20. Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.
Phongsamart W; Jantarabenjakul W; Chantaratin S; Anugulruengkitt S; Suntarattiwong P; Sirikutt P; Kosalaraksa P; Maleesatharn A; Chokephaibulkit K
J Int AIDS Soc; 2022 Jan; 25(1):e25862. PubMed ID: 35001501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
